



**THE 27th TEL-AVIV UNIVERSITY AD CONFERENCE &
First Joint UK-Israel Dementia Prevention**

June 17-19, 2019

Program

**Lectures will be held at the Dan David building, lecture hall # 3 on
the Tel Aviv University campus**

Chairs: First Joint UK-Israel Dementia Prevention Robert Perneczky
& Amos Korczyn, Imperial College London, UK/ Tel Aviv University,
Israel.

The 27th Tel Aviv AD conference Amos Korczyn, Danny Frenkel, Danny
Michaelson. Tel Aviv University

Monday, 17 June 2019

08.00-08.30	Registration + coffee
08.30-08.45	Welcome and opening presentations Robert Perneczky & Amos Korczyn, Imperial College London, UK/ Tel Aviv University, Israel
08.45-09.15	Israel opening presentation: The Israel national plan to address and prevent Alzheimer's disease and other dementias Shelley Sternberg, Ministry of Health, Israel
09.15-09.45	UK opening presentation: How far are we from curing Alzheimer's disease Susan Greenfield, House of Lords, UK

Session 1. Risk and protective factors I

Chairs: Gill Livingston & Eli Wertman, University College London, UK/ Hebrew University Jerusalem, Israel

- | | |
|--------------------|--|
| 9.45-10.10 | Changing the prevalence and incidence of dementia
Gill Livingston, University College London, UK |
| 10.10-10.35 | Obesity, brain, and cognition
Michal Schnaider Beeri , Sheba Medical Center, Israel , Department of Psychiatry, Icahn School of Medicine at Mount Sinai, NY |
| 10.35-11.00 | Effect of physical activity, APOE4 and plasma amyloid-beta on cognition function in healthy older adults
Catherine Robb, Imperial College London, UK |
| 11.00-11.25 | Can lifestyle changes reduce the incidence of dementia?
Yakir Kaufman, Herzog Medical Center Jerusalem, Israel |
| 11.25-11.45 | Coffee break |

Session 2. Data blitz: Early-stage researchers - blue sky

Chairs: Robert Pernecky & Illana Gozes, Imperial College London, UK/ Tel Aviv University, Israel

- | | |
|-------------|--|
| 11.45-11.50 | A possible new blood biomarker for AD
Paul Morrill, Neuro-Bio Ltd, UK |
| 11.50-11.55 | The effects of ApoE4 on membrane trafficking of ABCA1
Roni Bar, Tel Aviv University, Israel |
| 11.55-12.00 | Artificial cells with controllable central dogma activities as a tool for understanding complex biological events
Shai Zilberzwige –Tal, Tel Aviv University, Israel |
| 12.00-12.05 | Targeting brain metabolic impairment in an AD mouse model
Yuval Nash, Tel Aviv University, Israel |
| 12.05-12.10 | Arrested autophagy mediated by GSK-3 enhances mutant-huntingtin aggregates accumulation
Ido Rippin, Tel Aviv University, Israel |
| 12.10-12.15 | Illuminating disorientation across the Alzheimer's disease spectrum through the use of functional, structural and metabolic neuroimaging
Gregory Peters-Founshtein, Hadassah Hebrew University Medical Center, Israel |

12.15-12.20 | Maternal DNA-immunization strategy targeting amyloid- β related neuropathology and dementia in Down syndrome
Tomer Illouz, Bar-Ilan University, Israel

12.20-13.30 | Lunch break

Session 3. Preclinical research and small animal studies

Chairs: Danny Michaelson & Peter St George-Hyslop, Tel Aviv University, Israel/
University of Cambridge, UK

13.30-13.55 | Development of ApoE targeted Alzheimer's disease therapy
Daniel Michaelson, Tel Aviv University, Israel

13.55-14.20 | Impairments of neural circuit function in Alzheimer's mouse models
Marc Aurel Busche, Dementia Research Institute, UK

14.20-14.45 | Extra-hippocampal learning and memory deficits in young ApoE4 expressing rodents
Anan Moran, Tel Aviv University, Israel

14.45-15.10 | Microglial diversity and neuroinflammation in neurodegeneration
Peter St George-Hyslop, University of Cambridge, UK

15.10-15.30 | Coffee break

Session 4. Risk and protective factors II

Chairs: Amir Glik & Raj Kalaria, Rabin Medical Center, Israel/ University of Newcastle, UK

15.30-15.55 | Long-term cognitive outcomes after stroke in the COGFAST study
Raj Kalaria, University of Newcastle, UK

15.55-16.20 | Gait and cognitive decline in old age
Anat Mirelman, Tel Aviv Sourasky Medical Center, Israel

16.20-16.45 | Hearing loss and dementia risk
Sergi Costafreda Gonzalez, University College London, UK

16.45-17.10 | Antidepressant Medication and the Risk of Dementia
Stephen Levine, University of Haifa, Israel

18.30-22.00 | Speakers' dinner

Tuesday, 18 June 2019

08.30-09.00	Registration + coffee
09.00-09.05	Welcome Robert Perneczky & Amos Korczyn, Imperial College London, UK/ Tel Aviv University, Israel

Session 5: Interventions to prevent neurodegeneration and dementia

Chairs: Patrick Kehoe & Abdalla Bowirrat, University of Bristol, UK/ Bar Ilan University-Galilee, Israel

09.05-09.30	Application of the gene editing tool CRISPR-Cas9 for studying and treating Alzheimer's disease Daniel Offen, Tel Aviv University, Israel
09.30-09.55	Dysfunctional RNA metabolism in neurodegeneration Marc-David Ruepp, King's College London, UK
09.55-10.20	Obesity and dementia Ramit Ravona-Springer, Sheba Medical Center, Israel
10.20-10.45	The Reducing pathology in Alzheimer's Disease through Angiotensin taRgeting study (RADAR) Patrick Kehoe, University of Bristol, UK
10.45-11.05	Coffee break

Session 6: Clinical studies

Chairs: Ronit Pinkas-Kramraski & Klaus Ebmeier, Tel Aviv University, Israel/ University of Oxford, UK

11.05-11.30	Lifebrain project: determinants of brain, cognitive and mental health at different stages of life Klaus Ebmeier, University of Oxford, UK
11.30-11.55	Sleep and dementia Yuval Nir, Tel Aviv University, Israel
11.55-12.20	Ageing and sleep: insights from animal models Vladyslav Vyazovskiy, University of Oxford, UK
12.20-12.45	A simple tool to reach populations at risk for developing dementia Noa Bregman, Tel Aviv Sourasky Medical Center, Israel
12.45-13.45	Lunch break

Session 7: Risk and protective factors III

Chairs: Tamas Revesz & Odelia Elkana, University College London, UK/ Academic College of Tel Aviv-Yaffo, Israel

13.45-14.10	Neuroimaging correlates of cognitive reserve Robert Perneczky, Imperial College London, UK
14.10-14.35	Chronic traumatic encephalopathy as a neuropathological entity Tamas Revesz, University College London, UK
14.35-15.00	AD: past, present and future Amos Korczyn, Tel Aviv University, Israel
15.00-15.25	Neuromodulation of human memory: implications for AD Itzhak Fried, Tel-Aviv Medical Center , Israel
15.25-15.50	Closing words
15.50-16.30	Coffee

Wednesday, 19 June 2019

08.00-08.30 Registration + coffee

Session 8: Neuroinflammation

Chairs: Danny Frenkel & Eitan Okun, Tel Aviv University / Bar Ilan University

- | | |
|-------------|---|
| 08.30-09.10 | Modulating innate immunity in Alzheimer's disease
Michael Heneka, German Center for Neurodegenerative Diseases (DZNE), Germany |
| 09.10-09.30 | The role of Apoe in microglia regulation in neurodegeneration
Oleg Butovsky, Harvard Medical School, USA |
| 09.30-09.50 | CSF exchange therapy for the treatment of inflammatory degenerative diseases of the CNS
Hanna Rosenmann, Hadassah Hebrew University Medical Center, Israel |
| 09.50-10.10 | Altered autophagy and mitochondrial dynamics in APOE4-expressing astrocytes
Eran Schmukler, Tel Aviv University, Israel |
| 10.10-10.30 | Senescent astrocytes are affiliated with impaired cognition in 5xFAD mice.
Shoshik Amram, Tel Aviv University, Israel |
| 10.30-10.50 | Coffee break |

Session 9. Therapy and metabolism

Chairs: Menahem Segal & Abraham Fisher, Weizman Institute, Israel.

- | | |
|-------------|---|
| 10.50-11.10 | NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies
Illana Gozes, Tel Aviv University, Israel |
| 11.10-11.30 | Brain targeting of conjugated linoleic acid, a Calpain inhibitor, preserves memory and reduces A-beta and P25 accumulation in 5xFAD mice
Ruth Gabizon, Hadassah Hebrew University Medical Center, Israel |
| 11.30-11.50 | Unraveling the X factor in AD: VEGF as a novel therapeutic treatment for ApoE4
Shiran Salomon-Zimri, Tel Aviv University, Israel |

11.50-12.10	Idiosyncratic effects of putative N-glycosylation sites in human Tau on AD-related neurodegeneration Yelena Losev, Tel Aviv University, Israel
12.10-12.30	Borderline levels of serum vitamin B12 may predict cognitive decline in elderly hip fracture patients Eliyahu Mizrahi, Shmuel-Harofe hospital, Israel
12.30-12.50	Multifaceted Mitigating Effects of Hyperbaric Oxygen Therapy in Alzheimer's Disease Mouse Models Ronit Shapira, Tel Aviv university
12.50-13.50	Lunch break

Session 10. Neurodegeneration and molecular mechanisms

Chairs: Uri Ashery & Beka Solomon, Tel Aviv University, Israel

13.50-14.30	Axons, trauma and neurodegeneration Gorazd Bernard Stokin, St. Anne's University Hospital, Czech Republic
14.30-14.50	Non-coding RNAs in neurodegenerative diseases Mona Soreq, The Hebrew University of Jerusalem, Israel
14.50-15.10	Classification and prediction of clinical FTD diagnosis based on plasma microRNAs Iddo Magen, Weizmann Institute, Israel
15.10-15.30	Decoding the genomic architecture of late onset AD using single cell-type omics analyses Ornit Chiba-Falek, Duke University, USA
15.30-15.50	Norvaline as a novel AD-modifying agent Baruh Polis, Bar-Ilan University, Israel
15.50-16.10	Concluding remarks Amos Korczyn, Danny Michaelson, Danny Frenkel, Tel Aviv University, Israel

Sponsored by: The National Institute for Psychobiology in Israel,
Rabin Institute of Neurobiology,
Sagol School of Neuroscience.